Search company, investor...



Acquired | Acquired

Total Raised




About SpiroGen

The Spirogen group was founded in 2001 as a spin-out from several institutions including University College, London and partly funded by Cancer Research UK.The group has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell. This blocks the cancer cells' division without distorting its DNA helix, thus potentially avoiding the common phenomenon of emergent drug resistance. Spirogen has been developing its PBD technology for more than ten years, including a standalone PBD agent already in a clinical study in acute myeloid leukemia (AML). The company's business model has been to partner its technology with pharma and biotech for use in the development of novel drugs.

Headquarters Location

The QMB Innovation Centre

London, England, E1 2AX,

United Kingdom


Missing: SpiroGen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SpiroGen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing SpiroGen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SpiroGen is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

SpiroGen Patents

SpiroGen has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Stem cells, Transcription factors, Biotechnology, Cell biology, Induced stem cells


Application Date


Grant Date



Related Topics

Stem cells, Transcription factors, Biotechnology, Cell biology, Induced stem cells



Latest SpiroGen News

Hear the Keynote Addresses from MedImmune and Spirogen this April

Jan 17, 2018

Learn more about: – New and novel payloads, e.g. – Using minor-groove binding DNA-interactive molecules as ADC payloads. – The practicalities of the use of Highly Potent Active Pharmaceutical Ingredients within ADC development. – Using fragment drug conjugates to develop a more tailored therapy for solid tumours. – Design principles for maximising the drug delivery efficiency and therapeutic index. Day 1: Compare new generation HER-2 ADCs with Kadcyla™, examine technological advancements on PK-PD, highly potent ingredients, adc payloads and explore drug designs for ADCs; whilst Day 2 takes a look at fragmented drug conjugates and therapeutic windows, warheads and site selectivity, immune-oncological combination therapies, and design principles for maximising drug delivery. Day 1 Keynote Address: PBDs – Update on an Efficient & Effective Payload Class: Hear from Spirogen as they discuss one of the main aspects of ADCs; payloads, advanced methods of characterisation will be extremely important as this class of biologics (ADC payloads) is translated to industrial-scale production. Whether or not PBDs make better payloads than others, the clinical progress and current uses of PBDs with case study examples and new PBD payloads in developments; consequences on mode of action, efficacy and tolerability. PBDs are a class of DNA-crosslinking agents, they are significantly more potent than systemic chemotherapeutic drugs. Benefit from Arnaud Tiberghien, Scientist II, Chemistry, Spirogen who will explain the challenges and the significance of PBD payloads. Presented to you by: Arnaud Tiberghien, Scientist II, Chemistry, Spirogen Day 2 Keynote Address: Guided Warhead Loaded Missiles of ADCs in Fight Against Deadly Cancers: Challenges and Opportunities: Current antibody-drug conjugates in development have immense promise, but they are limited by the fact that they are structurally heterogeneous populations in which the position and number of conjugated linkers and warheads vary significantly. MedImmune will explore the target, linker, warhead selection: Do’s and Don’ts; five rights of creation of the best optimized fit-for-purpose ADCs; internalisation of ADCs – how to improve internalisation, lysosomal delivery and intracellular target hit and increasing the effectiveness of the ADCs by effective tumour targeting minimising the off-target toxicity of ADCs. Presented to you by: Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc Further information is available at: SMi presents the 6th Annual Conference: ADC Summit Location: Copthorne Tara Hotel, London UK Website:

SpiroGen Frequently Asked Questions (FAQ)

  • Where is SpiroGen's headquarters?

    SpiroGen's headquarters is located at The QMB Innovation Centre, London.

  • What is SpiroGen's latest funding round?

    SpiroGen's latest funding round is Acquired.

  • How much did SpiroGen raise?

    SpiroGen raised a total of $16.45M.

  • Who are the investors of SpiroGen?

    Investors of SpiroGen include MedImmune, Auven Therapeutics, Cambridge Research & Innovation, Research Corporation Technologies and UCL Business.

  • Who are SpiroGen's competitors?

    Competitors of SpiroGen include Kiadis Pharma, Annovis Bio, Esperance Pharmaceuticals, OncoMed Pharmaceuticals, Activate Immunotherapy, InClinica, Syndax Pharmaceuticals, Ikaria, LIDDS, RetroScreen Virology and 32 more.

Compare SpiroGen to Competitors

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Charleston Laboratories

Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states.

Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.


Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.